Lifeboat Foundation

NEW ORLEANS— Donated immune cells mixed with a molecule that helps them home in on tumor cells have dramatically shrunk tumors in most of the 22 people with blood cancer who received experimental infusions. The results, reported yesterday at the annual meeting of the American Association for Cancer Research (AACR), are a new twist on cell therapies that harness a patient’s own immune cells to treat cancer. The new treatment is simpler to make than other cell therapies for advanced lymphoma, or cancer of the lymph system, the study’s leaders say.

“It’s an interesting idea,” says hematologist and oncologist Jeffrey Miller of the University of Minnesota, Twin Cities, who was a panelist at the plenary session where the work was presented.

CAR-T cells, immune cells genetically modified to carry a surface protein that helps them home in on cancer cells, are the best known cancer cell therapy. Although approved for some types of leukemia and lymphoma, CAR-T cells can cause serious side effects and must be custom-made from a person’s own T cells.

High-amplitude ultrasound pulses have been used to partially destroy liver tumors in rats, triggering the rodents’ immune systems to clear the remaining cancerous cells and prevent the disease from spreading or returning. Presenting their findings in the journal Cancers, the researchers behind this breakthrough say their technique could lead to effective, non-invasive treatments for some of the most intractable cancers in human patients.

Liver cancer certainly falls into that category, and is associated with a five-year survival rate of just 18 percent in the US. Though many treatment options are available, liver tumors have a tendency to metastasize or recur after these interventions.

In their study, the authors explain that conventional cancer treatments like chemotherapy, radiotherapy, and thermal ablation are effective at destroying tumors, yet also trigger a somewhat unpredictable immune reaction which can be anti-tumor or pro-tumor. Furthermore, they note that the size, location, and stage of a tumor can sometimes make it impossible to target the entire tissue mass with existing treatments.

Elon Musk believes his Neuralink brain chip could help treat morbid obesity. Experts say the billionaire’s dream isn’t as far-fetched as it may seem.

“I don’t think it is any more implausible than other claims for the potential of neurotechnology,” Professor Andrew Jackson, an expert in neural interfaces at Newcastle University, told Insider.

Continue reading “Elon Musk said his Neuralink brain chip could help treat morbid obesity. Scientists say it’s a long shot — but not an impossibility” »

This is not the first successful research on de-ageing cells. Earlier, Shinya Yamanaka, a Nobel prize-winning stem cell researcher, genetically reprogrammed the mouse skin cells and turned them into induced pluripotent stem cells, or iPSCs, back in 2006. These cells type had the potential to form any cell type in the body. Yamanaka’s method took 50 days and completely reprograms cells to the biological age of an embryo. Gill’s method only took 13 days.

In a statement, Gill said, “Our results represent a big step forward in our understanding of cell reprogramming. We have proved that cells can be rejuvenated without losing their function and that rejuvenation looks to restore some function to old cells.”

Join us on Patreon!
https://www.patreon.com/MichaelLustgartenPhD

Papers referenced in the video:
Dietary oxalate to calcium ratio and incident cardiovascular events: a 10-year follow-up among an Asian population.
https://pubmed.ncbi.nlm.nih.gov/35346210/

Continue reading “How Much Oxalate Is Too Much? n=1 Analysis” »

New evidence shows that cancer is not as heritable or purely genetic as once thought, and taking a multi-omics approach may lead to a better understanding of how to prevent and treat it.

Cannabotech (CNTC.TA), which is involved in the development of a botanical drug based on an extract of the Cyathus striatus fungus and a cannabinoid extract from the cannabis plant, reports that in experiments conducted on a cell model, the fungus extract eliminated 100% of pancreatic cancer cells relatively selectively and without damaging normal cells.

What Happened

The fungus has been the subject of research to test its anti-cancer efficacy in prof. Fuad Fares’ laboratory at the University of Haifa for about eight years. It was selected as the preferred candidate for the development of a drug for pancreatic and colon cancer after showing better anti-cancer results than a variety of other fungi tested. A few months ago, Cannabotech received global and exclusive rights of use for patents created in Fares’ research and began leading an accelerated process of developing a botanical drug as defined by the FDA.

This is a 10-minute version with my picks on an hour-and-a-half interview on the longevity science made by Rhonda Patrick to Morgan Levine.

The link to the entire interview, which took place on April 12, 2022, is in the description of the video.

Continue reading “Morgan Levine is interviewed by Rhonda Patrick on Longevity. My picks on it” »